Dishman Carbogen Amcis Ltd. has announced its Q3 and 9MFY26 results, showcasing a revenue of Rs. 7,198 million for Q3FY26 and Rs. 20,805 million for 9MFY26. The company saw growth in CDMO segment revenue while marketable molecules segment revenue decreased in Q3 but increased over the nine-month period. Overall, the results reflect a positive trajectory driven by specific segments and strategic advantages.
Financial Highlights for Q3 & 9MFY26
Dishman Carbogen Amcis Ltd. reported a net revenue of Rs. 7,198 million in Q3FY26, compared to Rs. 6,823 million in Q3FY25. For the nine-month period (9MFY26), the company’s net revenue stood at Rs. 20,805 million, up from Rs. 19,952 million in 9MFY25.
The company’s EBITDA for Q3FY26 was Rs. 1,131 million, compared to Rs. 1,401 million in the corresponding quarter of the previous year. The 9MFY26 EBITDA reached Rs. 4,027 million, surpassing the Rs. 3,163 million recorded in 9MFY25.
EBITDA margin for Q3FY26 was 15.7%, while for 9MFY26, it stood at 19.4%.
Segment Performance
The CDMO segment contributed Rs. 6,297.4 million in Q3FY26, a 6.7% increase compared to Rs. 5,901.0 million in Q3FY25. The 9MFY26 revenue for CDMO was Rs. 17,503.8 million, slightly higher than the Rs. 17,234.4 million in 9MFY25.
Marketable Molecules segment recorded revenue of Rs. 900.6 million in Q3FY26, a decrease of -2.4% from Rs. 922.3 million in Q3FY25. However, for 9MFY26, the revenue increased to Rs. 3,301.2 million from Rs. 2,717.2 million in 9MFY25, a 21.5% increase.
Key Highlights and Factors
The increase in net revenue for Q3FY26 was primarily driven by higher revenue from the CDMO segment. The overall increase in 9MFY26 was mainly due to higher Cholesterol and Vitamin D analogues revenue contribution.
The CDMO revenue was higher by 6.7% compared to Q3FY25 due to higher development revenue.
A decrease in marketable molecules segment revenue for Q3FY26 was primarily due to lower Quats revenue, but an increase of 21.5% in 9MFY26 was due to an increase in Cholesterol and Vitamin D analogues supplies.
Source: BSE
